FDA declines to approve Summit’s lung cancer drug ivonescimab
|
The facts
- The FDA declined to approve Summit Therapeutics’ application for ivonescimab.
- The application covered ivonescimab with chemotherapy for previously treated advanced non-small cell lung cancer.
- The FDA said the trial did not show a statistically significant overall-survival benefit.
- The trial found ivonescimab delayed disease progression.
- The FDA concluded progression-free survival alone did not support approval.
- Akeso developed ivonescimab and markets it in China.
- Summit holds rights to develop and commercialize ivonescimab outside China.
Context
What did the FDA’s decision mean for U.S. patients?
Ivonescimab with chemotherapy was not approved in the United States for the proposed group of patients with advanced non-small cell lung cancer. Medindia EconoTimes
Why did the FDA decline the application?
The FDA said the trial did not establish a statistically significant improvement in overall survival and that delayed disease progression alone did not support approval. Reuters NASDAQ Stock Market STAT
Who developed ivonescimab?
Chinese drugmaker Akeso developed the drug and markets it in China, while Summit acquired rights to develop it outside China. NYT Spokesman Review STAT
Common ground, and where they split
- Common ground
- Both frames agree the trial delayed disease progression but showed no statistically significant overall-survival benefit, and that gap drove the FDA's rejection.
- Where Left and Right split
- The left and the right split on whether survival proof must come first, or patients deserve the choice anyway.
- Why they differ
- The divide is one of trust in institutional standards: whether a single statistical threshold for survival should override clinical evidence of slowed disease progression.
How left and right read it
Patients with previously treated advanced lung cancer deserve a drug that helps them live longer, not one that merely delays a scan result, and that is the line the agency held when it declined to approve ivonescimab with chemotherapy. The trial delayed disease progression, yet showed no statistically significant overall-survival benefit, so progression-free survival alone could not carry approval. Proof of survival comes first.
“The treatment, called ivonescimab, has become a symbol of China's rise in drug development.” — The New York Times
Patients and their doctors deserve weight for a treatment that measurably slows disease, not a verdict that one statistical test outweighs everything else. The trial delayed disease progression, yet the FDA rejected the application because it found no statistically significant overall-survival benefit and held that progression-free survival alone could not support approval. That is a regulator setting a rigid bar that forecloses relief a patient might reasonably choose for themselves.
The fight centers on whether a delayed scan result should be enough to approve a drug, or whether patients deserve that choice regardless.
The receipts — 30 sources
Wire services (4)
Other coverage (26)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.